



DATE: September 27, 2004 SHEET 1 of 2

Form PTO-1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE
(Modified) PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

5940.US.C3

SERIAL NO.

10/753,646

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

APPLICANT

D. J. Davidson, et al.

FILING DATE

January 8, 2004

GROUP

(37 CFR 1.98 (b))

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE
<i>HA</i>	A1	5 4 0 7 6 7 3	04/1995	Reich, et al.			
<i>HA</i>	A2	5 5 1 2 5 9 1	04/1996	Halperin, et al.			
	A3	5 8 5 4 2 2 1	12/1998	Cao, et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION
<i>HA</i>	B1	9 2 0 4 4 5 0	19.03.92	WO			YES NO
<i>HA</i>	B2	9 5 2 9 2 4 2	02.11.95	WO			
	B3	9 7 2 3 5 0 0	02.1997	WO			

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

<i>HA</i>	C1	SCRIP 2120:21 (4/16/96)
	C2	Fidler, I.J., et al., "The Implications of Angiogenesis for the Biology and Therapy of Cancer Metastasis", <i>Cell</i> , 79:185-188 (1994)
	C3	Folkman, J., "Clinical Applications of Research on Angiogenesis", <i>The New England Journal of Medicine</i> , 333(26):1757-1763 (1995)
	C4	Folkman, J., et al., "Angiogenesis", <i>Jour. of Biological Chemistry</i> , 267(16):10931-10934 (1992)
	C5	Folkman, J., et al., "Angiogenic Factors", <i>Science</i> , 235:442-447 (1987)
	C6	Gasparini, G., et al., "Clinical Importance of the Determination of Tumor Angiogenesis in Breast Carcinoma: Much More Than a New Prognostic Tool", <i>Jour. of Clinical Oncology</i> , 13(3):765-782 (1995)
	C7	Sottrup-Jensen, L., et al., "The Primary Structure of Human Plasminogen: Isolation of Two Lysine-Binding Fragments and One "Mini-" Plasminogen (MW, 38,000) by Elastase-Catalyzed-Specific Limited Proteolysis", <i>Progress in Chemical Fibrinolysis and Thrombolysis</i> , 3:191-209 (1978)
	C8	Kolberg, R., "Angiogenic Inhibitor Loss May Be Key To Post-Surgery Metastasis", <i>Journal of NIH Research</i> , 8:31-33 (1994)
	C9	McCance S., et al., "Amino acid residues of the Kringle-4 and Kringle-5 domains of human plasminogen that stabilize their interactions with omega-amino acid ligands", <i>Journal of Biological Chemistry</i> , 269:32405-32410 (1994)
	C10	Menhart, N., et al., "Functional Independence of the Kringle 4 and Kringle 5 Regions of Human Plasminogen", <i>Biochemistry</i> , 32:8799-8806 (1993)
	C11	Novokhatny, V. V., et al., "Domains in Human Plasminogen", <i>J. Mol. Biol.</i> , 179:215-232 (1984)
	C12	O'Reilly, M. S., et al., "Angiostatin: A Novel Angiogenesis Inhibitor That Mediates the Suppression of Metastases by a Lewis Lung Carcinoma", <i>Cell</i> , 79:315-328 (1994)
	C13	Teicher, B. A., et al., "Antiangiogenic Agents Can Increase Tumor Oxygenation and Response to Radiation Therapy", <i>Radiation Oncology Investigations</i> , 2:269-276 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)

DATE: September ____, 2004 SHEET 2_ of 2_

Form PTO - 1449 (Modified)

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (Modified) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 CFR 1.98 (b))	ATTY. DOCKET NO.	SERIAL NO.
	5940.US.P2	08/851,350
	APPLICANT	
	D. J. Davidson, et al.	
	FILING DATE	GROUP
	May 5, 1997	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUB CLASS	FILING DATE

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

DOCUMENT NUMBER	PUBLIC- ATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUB CLASS	TRANS- LATION
					YES NO

OTHER DOCUMENTS (Including Author, Title, Date, Place of Publication)

C14	Teicher, B. A., et al., "Antiangiogenic Agents Potentiate Cytotoxic Cancer Therapies against Primary and Metastatic Disease", <i>Cancer Research</i> , 52:6702-6704 (1992)
C15	Teicher, B. A., et al., "Antiangiogenic Treatment (TNP-470/Minocycline) Increases Tissue Levels of Anticancer Drugs in Mice Bearing Lewis Lung Carcinoma", <i>Oncology Research</i> , 7(5):237-243 (1995)
C16	Teicher, B. A., et al., "β-Cyclodextrin tetradecasulfate/tetrahydrocortisol + minocycline as modulators of cancer therapies in vitro and in vivo against primary and metastatic lewis lung carcinoma", <i>Cancer Chemother Pharmacol</i> , 33:229-239 (1993)
C17	Teicher, B. A., et al., "Influence of an Anti-Angiogenic Treatment on 9L Gliosarcoma: Oxygenation and Response to Cytotoxic Therapy", <i>Int. J. Cancer</i> , 61:732-737 (1995)
C18	Teicher, B. A., et al., "Potentiation of Cytotoxic Cancer Therapies by TNP-470 Alone and With Other Anti-Angiogenic Agents", <i>Int. J. Cancer</i> , 57:920-925 (1994)
C19	Teicher, B. A., et al., "Potentiation of cytotoxic therapies by TNP-470 and minocycline in mice bearing EMT-6 mammary carcinoma", <i>Breast Cancer Research and Treatment</i> , 36:227-236 (1995)
C20	Thewes, T., et al., "Isolation purification and 1H-NMR characterization of a kringle 5 domain fragment from human plasminogen", <i>Database Medline</i> , (1987)
C21	Thewes, T., et al., "Ligand Interactions with the Kringle 5 Domain of Plasminogen", <i>Journal of Biological Chemistry</i> , 265(7):3906-3915 (1990)
C22	Váradi, A., et al., "Kringle 5 of human plasminogen carries a benzamidine-binding site", <i>Biochemical and biophysical Research Communications</i> , 103:97-102 (1981)
C23	Weidner, N., et al., "Tumor Angiogenesis and Metastasis - Correlation in Invasive Breast Carcinoma", <i>The New England Journal of Medicine</i> , 324(1):1-8 (1991)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

(Form PTO-1449)